Article in PDF
How to Cite
Citation Manager
Readers' Comments (0)
Audio Visual Article Statistics
Link
to PUBMED
Print this Article
Send to a Friend
Advertisers
Access Statistics Resources
Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."
Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
E-mail: drrajendrak1@rediffmail.com
On May 11,2011
Dr. Shankar P.R.
"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."
Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
E-mail: ravi.dr.shankar@gmail.com
On April 2011 Anuradha
Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.
Dr. Anuradha
E-mail: anuradha2nittur@gmail.com
On Jan 2020
Case report
Full Version
Metatypical Carcinoma: A Rare Case Report
Correspondence Address :
Dr. Kalpana Kumari M.K.
Flat 710, C-Block, Sterling Residency,
Dollars Colony, Bangalore 560094
Karnataka, India.
Phone: 9886392301
E-mail: kalpank@gmail.com
Metatypical carcinoma is a carcinoma of the skin with intermediate features of basal cell carcinoma and squamous cell carcinoma. It is known for local recurrence and potential for distant metastatic spread. Metatypical carcinoma is a histopathological diagnosis hence a more accurate assessment with a thorough knowledge will be a necessity. Here we report a rare case of metastatic metatypical carcinoma to bone which is extremely rare.
Basal cell carcinoma, Metatypical carcinoma, Metastasis
INTRODUCTION
Skin cancers are the most common type of cancer, accounting for about half of all human cancers (1). Non-melanoma skin cancers which include basal cell carcinoma and squamous cell carcinoma are the most frequent malignant conditions worldwide. Basal cell carcinomas are found predominantly on areas of skin exposed to sun (2). Basosquamous carcinoma also known as metatypical carcinoma with features of both squamous and basal cell carcinoma has an incidence rate of 1-2% of all cancers of skin. This has to be considered as another entity with its own distinct features with rates of metastasis reported upto 7.4% (3).
A 56-year-old female presented with complaints of nodule on right ala of nose from 3 weeks in November 2009 which was 1x1 cm in size. The lesion had a smooth surface, hard in consistency and not associated with pain or tenderness. There was no evidence of cervical lymphadenopathy. Patient underwent excision biopsy of the lesion on nose following which it resolved completely. Biopsy suggested of metatypical basal cell carcinoma. Patient was asymptomatic for 3 months following which she presented with a right cervical mass FNAC of which showed metastatic deposits. Patient underwent right side Type II comprehensive neck dissection. Histopathology report showed level I & II – 5 nodes free of tumor, level III - 36 nodes free of tumor, level IV and V – 1 out of 8 lymph nodes showed metastatic carcinoma with perinodal spread. Adjuvant RT was given with 60 Gy in 30 fractions to neck and 40 Gy in 15 fractions to nasal vestibule using IMRT. Patient was asymptomatic till January 2010 then she presented to our institute with complaints of backache and difficulty in walking. On examination, tenderness was elicited on D6 spinous process with increased tone and brisk reflexes in the lower limbs. Also a nodular, non-tender swelling was noted in the occipital region of the skull. X-ray showed evidence of a lytic lesion in the occipital region, dorsolumbar spine showed osteoporotic changes in the vertebral body, appendages and disc appear normal, the right femur showed a small lytic lesion and Chest X-ray was normal. MRI of spine showed D6 vertebral lesion suggestive of metastasis, T5 to T7 showed extra-dural lesion with moderate cord compression. Bone scan showed metastasis in right posterior parieto-occipital bone, D6 vertebra and midshaft of right femur. USG abdomen and pelvis was essentially normal. Patient underwent D6 Laminectomy. Post-operatively wounds healed satisfactorily. Histopathological examination showed highly undifferentiated metastatic carcinoma. Second review of the histopathology slides was done which suggested metatypical carcinoma. Palliative Radiotherapy to occipital region, right mid shaft of femur and D6 vertebra was given. At 6 months post-surgery, swelling over the skull regressed in size, power in the lower limbs is intact with persisting spasticity. Patient is able to walk with support. Femoral lesion is ossified.
Non-melanoma skin cancers are the most common cancer in US, UK and Australia (1). There is an increase in incidence of skin cancers which can be attributed to increased detection and awareness (2). The incidence of non- melanoma skin cancers varies based on geographic location with highest rates of 1-2% per year in places like Australia (3). Basosquamous carcinoma is a lesion that is continuum of basal cell carcinoma and squamous cell carcinoma. Basal cell carcinoma undergoes squamous cell differentiation and that alters its biologic behavior. These intermediate lesions have a greater tendency to recur and metastasize (4). However some authors say the mode of metastatic spread and characterstics of the histology make it rather unlikely that metastasis of the basal cell carcinoma is due to a change toward squamous cell carcinoma (5). We report here a case of metatypical carcinoma with metastasis to the bone. The incidence of metastatic basal cell carcinoma is only 0.0028-0.5% (2). In the review of 170 case, von Domarus (5) found that the median age of onset was 45-years, the median interval between the diagnosis and metastatic lesion was 9 years. For our patient the age of onset was 56-years and it metastasized within 3 months. Generally it metastasizes to lymph nodes and lung and less commonly to bone and internal organs (6). Men are more predisposed to metastatic basal cell carcinoma than women by a ratio of 2:1 (2), (7). Our case was a female. An Indian series has reported an unusual female preponderance (7). Metastatic basal cell carcinoma was first reported in 1894 in a 46 year old man with metastases to submaxillary lymph node. Since then there have been only about 300 cases of metastatic basal cell carcinoma reported in scientific literature over the last 110 years (8). The criteria for the diagnosis of metastatic basal cell carcinoma were first defined by Lattes and Kessler (9) in 1985:
1. The primary tumour must originate from the skin and not the mucosa.
2. Metastasis cannot be by simple extension but must occur at a site distant from primary tumour.
3. The primary and the metastatic tumor must have similar histologic subtypes.
Blewitt reviewed 38 cases of metastatic basal cell carcinoma and noted that the primary tumour was usually located on face or scalp (10). In our case it was located on right ala of nose. It has been postulated that the presence of embroyogenic fusion planes in the midface area results in more occult and distant spread, as well as more difficult for surgical removal (11). On the other hand, the existence of basosquamous is questioned by many. It would seem that the entirely different genesis of squamous cell carcinoma, a tumour composed of immature rather than anaplastic cells, makes the occurrence of transitional forms quite unlikely. It can be assumed that the so called mixed type of basosquamous carcinoma represent a keratotic basal cell carcinoma and the intermediate type represents a basal cell carcinoma with differentiation into two types (12). The rarity of cases of metastatic basal cell carcinoma has limited the availability of various treatment strategies. The three modalities that have been used are surgery, radiotherapy and chemotherapy.8 The prognosis of metatypical carcinoma is generally poor.
Metatypical basal cell carcinoma are uncommon and metastasis to the bone is extremely rare, however as these are more aggressive, close and long term follow up for distant metastasis is suggested.
OI: JCDR/2012/3521:1948
Financial OR OTHER COMPETING INTERESTS:
None.
Date of Submission: Oct 31, 2011
Date of Peer Review: Jan 08, 2012
Date of Acceptance: Jan 09, 2012
Date of Publishing: May 01, 2012
- Emerging Sources Citation Index (Web of Science, thomsonreuters)
- Index Copernicus ICV 2017: 134.54
- Academic Search Complete Database
- Directory of Open Access Journals (DOAJ)
- Embase
- EBSCOhost
- Google Scholar
- HINARI Access to Research in Health Programme
- Indian Science Abstracts (ISA)
- Journal seek Database
- Popline (reproductive health literature)
- www.omnimedicalsearch.com